Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
2478 Street City Ohio 90255







Advancing patient safety with a commitment to excellence in drug development and beyond

CEO & Founder
MBBS, PhD (Pharmaceutical Medicine)
Certified Independent Director – IICA
Corporate Governance – The Wharton School
I’m an MBBS physician with a Ph.D., an ex-Sun Pharma leader (2007–Dec 2024), Certified Independent Director (IICA, Wharton) and currently founder of RXVP Pharma Consulting. With 20+ years in global drug development, life-cycle management, regulatory strategy & healthcare, I am actively building upon and aligning integration of AI and ESG with the pharmaceutical value chain across Discover, Develop, and Deliver.
My career has been driven by a commitment to bridging the gaps between drug development and patient care solutions. My interdisciplinary expertise spanning across medicine, pharmacology, pharmaceutical medicine, and clinical research enables me to formulate medical strategies & medical documents translating complex scientific concepts into practical strategies.
My aim is to enhance stakeholder’s financial performance by helping them expand their market presence through swift introduction of superior and innovative products through timely submissions, approvals, market launches-promotions; and managing product lifecycles to strengthen brand reputation.
Our products are certified by reputable organic.
Our products are certified by reputable organic.
Our products are certified by reputable organic.
Our products are certified by reputable organic.
Starting May, 2007 till Dec, 2024, I served in India’s largest generic drug manufacturer organization (Sun Pharmaceutical Ltd/Erstwhile Ranbaxy) after serving in healthcare settings post my medical degree in 1997. I established RXVP Pharma Consulting in January 2025, stepping into the role of Founder and Director.
As the Founder & CEO of RXVP Pharma Consulting, I offer services to global pharma organizations to streamline their product journeys from proof of concept and pre-clinical research to regulatory filings, approvals, market launches, and post-marketing safety and beyond, and act as an AI strategy and implementation advisor while continually advancing my expertise in the evolving AI landscape within pharma value chain. Proficient in development of medical documents.
While working in Sun Pharma in its medical affairs, clinical research & global pharmacovigilance (PVG) department, I led teams supporting successful drug approvals [generics, 505 (b)2/hybrid, branded, bibliographic] from global regulatory agencies including FDA, EMA, TGA, SAHPRA, MHRA, Health Canada, emerging markets & so on. Interacted with agencies during drug-dossier review/approval cycles. I led teams in PVG activities, supported BD/marketing teams in commercialization, physician-patient queries & portfolio expansion, facilitated drug recall decisions via HHAs & medical due-diligence of pharma companies, participated in regulated market PV inspections.
Strategic Vision: Expertise in devising & implementing strategies that align with evolving industry trends and regulatory frameworks.
Industry Recognition: Active member of the Institute of Directors India, reflecting a commitment to excellence in corporate governance (Wharton).
Published Author: My manuscripts are published in peer-reviewed journals and are indexed on PubMed.
Leadership: Proven track record in leading cross-functional teams; I align with leadership principles advocated by Goldsmith, Covey and Bill George.
Proficient in written & spoken Punjabi, Hindi & English; expert in MS Word & Power Point. Passionate about GenAI, RWE/RWD, ESG/CSR, corporate governance, & continuous self-development.

Our team of dedicated healthcare professionals combines years of experience with a genuine commitment to providing

Your health and well-being are our top priorities. We take the time to listen to your concerns, answer your questions.

We understand that every patient is unique, and their healthcare needs may vary. That's why we create individualized treatment.
“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”

“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”

“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”

“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”
